Arzuaga A, Isla A, Gascón A R, Maynar J, Corral E, Pedraz J L
Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain.
Blood Purif. 2006;24(4):347-54. doi: 10.1159/000092921. Epub 2006 Apr 25.
BACKGROUND/AIM: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone.
Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula.
Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH.
Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors.
背景/目的:哌拉西林-他唑巴坦常用于治疗重症监护病房(ICU)患者的感染。关于持续肾脏替代治疗(CRRT)期间哌拉西林的筛滤/饱和系数(Sc/Sa),已有相互矛盾的数据发表。目的是评估使用AN69和聚砜膜进行持续静静脉血液滤过(CVVH)和持续静静脉血液透析(CVVHD)时哌拉西林-他唑巴坦的Sc/Sa。
乳酸林格液、含牛血清白蛋白(BSA)的乳酸林格液和血浆以150 ml/min的速度循环。超滤/透析流量保持在1500 ml/min。注射一次大剂量药物并采集样本。使用高效液相色谱法(HPLC)测定药物。Sc/Sa根据标准公式计算。
据报道,药物在无蛋白溶液中可自由通过膜。在有蛋白质存在的情况下,Sc/Sa降低,且与无蛋白分数相关。在CVVH期间,聚砜膜的通透性显著高于AN69膜。
药物与白蛋白结合导致哌拉西林Sc/Sa降低,但这并不能完全解释一些作者所获得的体内值。